Travere Therapeutics (TVTX) Operating Expenses (2011 - 2026)

Travere Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $164.1 million for Q1 2026.

• Quarterly Operating Expenses rose 31.92% year-over-year to $164.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $593.3 million (up 18.46% YoY) and the FY2025 annual result came in at $553.6 million, down 0.62% from the prior year.
• Operating Expenses was $164.1 million for Q1 2026 at Travere Therapeutics, up from $162.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $180.6 million in Q1 2024 and bottomed at $95.4 million in Q1 2022.
• A 5-year average of $131.6 million and a median of $128.3 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 149.85% — and 2025, when it tumbled 31.12%.
• Travere Therapeutics' Operating Expenses stood at $116.0 million in 2022, then rose by 20.04% to $139.3 million in 2023, then slipped by 2.71% to $135.5 million in 2024, then rose by 19.62% to $162.1 million in 2025, then rose by 1.23% to $164.1 million in 2026.
• Business Quant data shows TVTX's Operating Expenses at $164.1 million in Q1 2026, $162.1 million in Q4 2025, and $139.9 million in Q3 2025.